Company news
Tanvex Biopharma, Inc. news
Latest news releases, newest first.
Tanvex Biopharma: Represent subsidiary Tanvex BioPharma USA,Inc. to announce BLA resubmission for TX01(Neupogen Biosimilar)
August 15, 2022
Tanvex Biopharma: The Company has been required by TWSE to announce the financial data according to the regulations
August 4, 2022
Tanvex Biopharma: Represent subsidiary Tanvex BioPharma USA,Inc. to announce the result of FDA inspection for TX05(Herceptin Biosimilar)(supplementary)
August 1, 2022
Tanvex Biopharma: Represent subsidiary Tanvex BioPharma USA,Inc. to announce the result of FDA inspection for TX05(Herceptin Biosimilar)
July 31, 2022
Tanvex Biopharma: Represent subsidiary Tanvex BioPharma USA,Inc. to announce that TX01(Neupogen Biosimilar) got Drug Establishment Licence from Health Canada
July 24, 2022
Announcement of the Board of Directors' resolution on the appointment of corporate governance officer
July 15, 2022
Announcement of new appointment of the Company's Remuneration Committee.
July 15, 2022
The Announcement of Resolutions of 2022 Annual General Shareholders’ Meeting(Add any other proposals)
June 17, 2022
Announcement of the Resolution of Annual General Meeting to Approve of Lifting of Non-Competition Restrictions for Board Director.
June 17, 2022
Announcement of One Newly By-Elected Independent Director at 2022 General Shareholders' Meeting of Tanvex
June 17, 2022
The Announcement of Resolutions of 2022 Annual General Shareholders’ Meeting
June 17, 2022
The Board of Directors approved the convening of the 2022 Annual General Shareholders' Meeting(add new discussion matters)
April 22, 2022
Resolution by the board of directors not to distribute dividends
March 21, 2022
The time, venue, and agenda of the 2022 annual general meeting.
March 21, 2022
The Board approved to issue Employees' Restricted Share Award
March 21, 2022
Appointment of the Chief Executive Officer and Chief Financial Officer (CFO)/Accounting officer
February 18, 2022